Last reviewed · How we verify

oral administration of S-1

Japan Clinical Oncology Group · Phase 3 active Small molecule

oral administration of S-1 is a Fluoropyrimidine antimetabolite Small molecule drug developed by Japan Clinical Oncology Group. It is currently in Phase 3 development for Gastric cancer, Colorectal cancer, Pancreatic cancer.

S-1 is an oral combination of tegafur, gimeracil, and oteracil that inhibits thymidylate synthase and fluorodeoxyuridylate synthase to block DNA synthesis in cancer cells.

S-1 is an oral combination of tegafur, gimeracil, and oteracil that inhibits thymidylate synthase and fluorodeoxyuridylate synthase to block DNA synthesis in cancer cells. Used for Gastric cancer, Colorectal cancer, Pancreatic cancer.

At a glance

Generic nameoral administration of S-1
SponsorJapan Clinical Oncology Group
Drug classFluoropyrimidine antimetabolite
TargetThymidylate synthase, dihydropyrimidine dehydrogenase
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

S-1 is a dihydropyrimidine dehydrogenase-inhibitory fluoropyrimidine prodrug combination. Tegafur is converted to 5-fluorouracil (5-FU), while gimeracil inhibits dihydropyrimidine dehydrogenase to enhance 5-FU bioavailability and reduce toxicity, and oteracil protects normal tissues. This combination achieves sustained anti-cancer effects with improved tolerability compared to standard 5-FU.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about oral administration of S-1

What is oral administration of S-1?

oral administration of S-1 is a Fluoropyrimidine antimetabolite drug developed by Japan Clinical Oncology Group, indicated for Gastric cancer, Colorectal cancer, Pancreatic cancer.

How does oral administration of S-1 work?

S-1 is an oral combination of tegafur, gimeracil, and oteracil that inhibits thymidylate synthase and fluorodeoxyuridylate synthase to block DNA synthesis in cancer cells.

What is oral administration of S-1 used for?

oral administration of S-1 is indicated for Gastric cancer, Colorectal cancer, Pancreatic cancer, Biliary tract cancer.

Who makes oral administration of S-1?

oral administration of S-1 is developed by Japan Clinical Oncology Group (see full Japan Clinical Oncology Group pipeline at /company/japan-clinical-oncology-group).

What drug class is oral administration of S-1 in?

oral administration of S-1 belongs to the Fluoropyrimidine antimetabolite class. See all Fluoropyrimidine antimetabolite drugs at /class/fluoropyrimidine-antimetabolite.

What development phase is oral administration of S-1 in?

oral administration of S-1 is in Phase 3.

What are the side effects of oral administration of S-1?

Common side effects of oral administration of S-1 include Bone marrow suppression (leukopenia, thrombocytopenia), Gastrointestinal toxicity (nausea, diarrhea, anorexia), Hand-foot syndrome, Stomatitis, Fatigue.

What does oral administration of S-1 target?

oral administration of S-1 targets Thymidylate synthase, dihydropyrimidine dehydrogenase and is a Fluoropyrimidine antimetabolite.

Related